^
    7ms
    RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
    P1/2, N=47, Completed, Oncoinvent AS | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> May 2025 | Trial primary completion date: Feb 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Radspherin
    over1year
    A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery (clinicaltrials.gov)
    P2, N=114, Recruiting, Oncoinvent AS
    New P2 trial • Surgery • Metastases
    |
    Radspherin
    almost2years
    Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=49, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
    Enrollment closed • Platinum sensitive • First-in-human
    |
    Radspherin
    almost2years
    RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
    P1/2, N=67, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Radspherin
    over2years
    Effect of Intraperitoneal Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy. (PubMed, Technol Cancer Res Treat)
    Our study showed a predominately local rather than systemic inflammatory response to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Radspherin® had overall modest impact on the inflammation.
    Journal • Surgery
    |
    IFNG (Interferon, gamma) • CCL4 (Chemokine (C-C motif) ligand 4) • IL1R1 (Interleukin 1 receptor, type I)
    |
    Radspherin
    over3years
    Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=49, Recruiting, Oncoinvent AS | N=33 --> 49 | Trial completion date: Oct 2023 --> Aug 2025 | Trial primary completion date: Dec 2022 --> Aug 2025
    Enrollment change • Trial completion date • Trial primary completion date • Platinum sensitive • First-in-human
    |
    Radspherin
    over3years
    RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
    P1/2, N=67, Recruiting, Oncoinvent AS | Phase classification: P1 --> P1/2 | N=39 --> 67 | Trial completion date: Mar 2023 --> Feb 2025 | Trial primary completion date: Dec 2022 --> Feb 2025
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Radspherin
    over5years
    Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=33, Recruiting, Oncoinvent AS | Not yet recruiting --> Recruiting
    Enrollment open • Platinum sensitive • First-in-human
    |
    Radspherin
    almost6years
    RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
    P1, N=39, Recruiting, Oncoinvent AS | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Radspherin
    6years
    RAD-18-002: Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
    P1, N=39, Not yet recruiting, Oncoinvent AS | Trial primary completion date: Dec 2020 --> Dec 2022
    Trial primary completion date
    |
    Radspherin
    6years
    Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Oncoinvent AS | Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Jan 2021 --> Dec 2022
    Trial completion date • Trial primary completion date • Platinum sensitive • First-in-human
    |
    Radspherin
    almost7years
    Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Oncoinvent AS | Trial completion date: Jun 2022 --> Feb 2023 | Initiation date: Feb 2019 --> Dec 2019
    Trial completion date • Trial initiation date • Platinum sensitive • First-in-human
    |
    Radspherin